COMMUNIQUÉS West-GlobeNewswire

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
28/10/2026
TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass., Oct. 28, 2026 (GLOBE [...]
Remix Therapeutics Selected for Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium
28/10/2026
Presentation to Include Updated Interim Data from Ongoing Phase 1/2 ARIA Study of REM-422 in Adenoid Cystic Carcinoma WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical- [...]
BPGbio Publishes Pioneering Research on Novel Brain-Penetrant Therapeutic Candidate for Glioma
28/10/2026
Preclinical study demonstrates potent anticancer activity, blood-brain barrier penetration, and improved survival in glioma models Findings highlight a novel therapeutic approach targeting microtubule dynamics, with [...]
Lumexa Imaging Announces Third Quarter 2026 Earnings Conference Call Date
28/10/2026
RALEIGH, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced it will release its third quarter 2026 financial and [...]
NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
28/10/2026
Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences, Inc. (“NovaBridge” or [...]
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
28/10/2026
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte [...]
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
28/10/2026
Conference Call Scheduled for November 4, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to- [...]
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
28/10/2026
REYKJAVIK, Iceland, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for [...]
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
28/10/2026
REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Axogen, Inc. Reports Third Quarter 2026 Financial Results
28/10/2026
Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million ALACHUA and TAMPA, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative [...]
Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera
28/10/2026
FAB-KLEAR investigates lucerastat as a potential disease-modifying therapy targeting the kidney manifestations of Fabry disease. Nxera will contribute to development and hold commercialization rights in Japan and [...]
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
28/10/2026
The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen. Most patients are diagnosed with [...]
Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets
28/10/2026
Nxera has exercised its option to license lucerastat for Japan, South Korea, Taiwan and selected other Asia Pacific markets (excluding China), paying Idorsia CHF 7 million upfront and contributing to the global Phase 3 [...]
15-year-old Designs Low-Cost Device to Monitor Airborne Bacteria in the Environment; Wins $25,000 Top Award at the 2026 Thermo Fisher Scientific Junior Innovators Challenge
28/10/2026
Young innovators awarded more than $100,000 for research on dementia-related proteins, alternatives to agricultural plastics and wildfire prevention Key Takeaways: Thermo Fisher Scientific and Society for Science [...]
Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
28/10/2026
Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung cancer. SHANGHAI, [...]
Latest Data of Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2026
28/10/2026
BEIJING, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that latest data of [...]
Newsweek Places KFSH in Top 4% of World's Smart Hospitals for Digital Maturity and AI
28/10/2026
RIYADH, Saudi Arabia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is one of only 15 hospitals worldwide to receive both the maximum five-ribbon digital maturity rating [...]
What Happens During a Dental Implant Consultation in Tukwila
27/10/2026
Candidacy for implants and All-on-X full-arch treatment is evaluated in a single visit, with 3D imaging and digital impressions done in-house. Implants are placed and restored by the same dentist at South Seattle Smiles [...]
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
27/10/2026
WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum